+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Next Generation Sequencing Data Analysis - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • PDF Icon

    Report

  • 180 Pages
  • October 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6292869
The next generation sequencing data analysis market size was valued at USD 1.10 billion in 2025 and is estimated to grow from USD 1.32 billion in 2026 to reach USD 3.32 billion by 2031, at a CAGR of 20.24% during the forecast period (2026-2031). This report is Segmented by Offering (Software, Services), Workflow (Primary, Secondary, Tertiary), Deployment Mode (Cloud-Based, On-Premise, Hybrid), Application (Clinical Diagnostics, Drug Discovery, Precision Medicine, Others), End User (Academic Institutes, Hospitals, Pharma/Biotech, Cros), and Geography (North America, Europe, Asia-Pacific, and More). Forecasts in Value (USD).

Global Next Generation Sequencing Data Analysis Market Trends and Insights

Expanding Clinical NGS Testing in Oncology and Rare Disease

The Next Generation Sequencing Data Analysis Market benefits as oncology moves from single-gene testing toward comprehensive genomic profiling. The proposed FDA reclassification in November 2025 would move oncology nucleic acid-based companion diagnostics from Class III PMA requirements to Class II 510(k) requirements under 21 CFR 866.6075. A lower regulatory threshold can increase companion diagnostic volumes without reducing the complexity of analyzing test results. Competition, therefore, depends more on analytical accuracy, reproducible pipelines, and the quality of clinical reporting. Rare disease programs add demand because whole-exome and whole-genome testing need tools for uncertain variant resolution and phenotype-genotype correlation. Software providers are responding with AI-supported interpretation functions that help laboratories manage these complex review tasks.

Cloud and Hybrid Compute Adoption

Cloud infrastructure helps institutions avoid building on-premises compute capacity for peak genomic workloads. Oxford Nanopore Technologies reported a 50% reduction in total cost of ownership compared with traditional local-storage pipelines in work supporting Singapore's national genome program. This model allows institutions to use compute resources when needed instead of purchasing capacity years in advance. The Next Generation Sequencing Data Analysis Market also faces greater dependence on a limited set of large cloud environments as analytical workloads move off site. That dependence can make data residency and workflow migration more difficult for users. Hybrid systems address this issue by keeping raw reads within an institution while using cloud resources for secondary and tertiary analysis.

Fragmented Data-Privacy and Data-Sovereignty Requirements

Data sovereignty rules determine where genomic data can be stored, processed, and shared in the Next Generation Sequencing Data Analysis Market. European requirements and the developing European Health Data Space framework can limit cross-border handling of citizen genomic data. These rules can fragment the collaborations that create large datasets for AI model training. SF-GWAS demonstrated privacy-preserving genome-wide association analysis on a UK Biobank cohort of 410,000 individuals with accuracy comparable to centralized models. Federated methods offer a practical response where data cannot cross institutional boundaries. Vendors still face added engineering and legal work when they operate jurisdiction-specific data environments across several geographies.

Other drivers and restraints analyzed in the report include:
  • AI and Machine Learning Convergence With Genomic Pipelines
  • Declining Sequencing Cost and Population-Scale Programs
  • Shortage of Clinically Trained Bioinformaticians and Validation Experts

Segment Analysis

Software held 58.31% of Next Generation Sequencing Data Analysis Market revenue in 2025. This Next Generation Sequencing Data Analysis Market share reflected institutional demand for integrated suites that cover primary, secondary, and tertiary analysis. Tertiary interpretation software has high value because it supports variant curation, clinical report generation, and decision support. These functions are close to diagnostic and therapeutic decisions. Secondary analysis software includes alignment, variant calling, and quality filtering functions. Hardware vendors increasingly incorporate this layer within their offerings, which can pressure standalone software margins.

Data management, storage, and workflow management tools are gaining use as institutions handle hundreds of terabytes of genomic information each year. These tools address data governance and pipeline coordination needs that general IT systems do not fully meet. Services are the fastest-expanding offering segment through 2031 because many institutions lack internal bioinformatics teams. Customized pipeline development is important for long-read, single-cell, and multiomics assays that require configuration beyond standard packages. Outsourced analysis, variant interpretation, and report generation provide hospital laboratories with clinical-grade outputs without building internal analytics infrastructure. The service model also supports contract research organizations that offer integrated sample-to-report workflows.

Tertiary analysis held 48.24% of workflow revenue in 2025 in the Next Generation Sequencing Data Analysis Market. The workflow covers variant annotation, phenotype-genotype correlation, clinical reporting, and AI-supported interpretation. Its position shows that the central challenge in NGS diagnostics is turning variant lists into evidence-backed clinical conclusions. Tertiary systems connect to electronic health records, genomic databases such as ClinVar and COSMIC, and regulatory reporting functions. These connections make the workflow more complex than earlier analysis stages. They also make tertiary tools more differentiated within clinical and translational settings.

Secondary analysis is the fastest-growing workflow segment through 2031. It includes read mapping, variant alignment, and variant calling. Long-read platforms from Oxford Nanopore Technologies and PacBio need secondary pipelines that handle reads extending to tens of kilobases. This differs from short-read pipelines designed for Illumina systems. Machine-learning models such as DeepVariant and Clair3 can improve calling accuracy while requiring specialized software infrastructure. Primary analysis remains the lowest-margin stage because instrument vendors increasingly include it in on-device or instrument-adjacent compute systems.

Complete Report Scope:

  • By Offering
    • Software
      • Primary Data Analysis Software
      • Secondary Analysis Software
      • Tertiary Analysis and Interpretation Software
      • Data Management and Storage Tools
      • Workflow Management Software
    • Services
      • Data Analysis Services
      • Data Management and Storage Services
      • Pipeline Development and Customization
      • Other Services
  • By Workflow
    • Primary Analysis
    • Secondary Analysis
    • Tertiary Analysis
  • By Deployment Mode
    • Cloud-Based
    • On-Premise
    • Hybrid
  • By Application
    • Clinical Diagnostics
    • Drug Discovery and Development
    • Precision Medicine
    • Genomic Research
    • Other Applications
  • By End User
    • Academic and Research Institutes
    • Hospitals and Clinical Laboratories
    • Pharmaceutical and Biotechnology Companies
    • Contract Research Organizations
    • Other End Users
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • South America
      • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 42.41% of the Next Generation Sequencing Data Analysis Market revenue in 2025. The region's position reflects sequencing capacity across academic medical centers, national laboratories, and pharmaceutical genomics groups. NIH All of Us links more than 535,000 whole-genome sequences with nearly 482,000 electronic health records in its June 2026 release. This scale supports continuing demand for analysis platforms and services. Canada and Mexico add demand through genomics programs and expanding biomedical research infrastructure. The United States has a large base of software licensing tied to installed Illumina systems and NGS-focused CRO activity.

Europe has a meaningful position in the Next Generation Sequencing Data Analysis Market, led by the UK, Germany, and France. National genomics programs in these countries support demand for scalable analytical infrastructure. Germany's genomDE initiative directs public resources toward genomic medicine infrastructure. The country's health insurance expansion for tumor profiling reimbursement in 2024 added an estimated 80,000 tests annually. France committed EUR 670 million (USD 720 million) at 2025 average exchange rates to 12 regional genomics platforms under its national plan. The EU IVDR transition increases the need for tools that support validated and documented laboratory workflows.

Asia-Pacific is the fastest-growing regional area through 2031. China benefits from MGI-driven sequencing cost reductions, India from an expanding biotechnology research base, and Japan from a reimbursement-supported clinical NGS setting. South Korea, Australia, and India contribute capacity through academic sequencing cores, health agency programs, and contract research expansion. The Middle East and Africa are earlier-stage areas led by GCC genomic medicine investments and South African research sequencing programs. Brazil's Genomas Brasil initiative shows how government-directed programs can shape genomic capacity in South America.


List of Companies Covered in this Report:

  • Agilent Technologies
  • BGI Genomics Co., Ltd.
  • Congenica Ltd.
  • DNAnexus, Inc.
  • DNASTAR, Inc.
  • Eurofins
  • Roche
  • Fabric Genomics, Inc.
  • Geneious Biomatters Ltd.
  • Golden Helix, Inc.
  • Illumina
  • Oxford Nanopore Technologies plc
  • Pacific Bioscience
  • Partek
  • QIAGEN
  • Revvity, Inc.
  • Sentieon Inc.
  • Seven Bridges Genomics, Inc.
  • SOPHiA GENETICS SA
  • Thermo Fisher Scientific

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 Research Methodology3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Expanding Clinical NGS Testing in Oncology and Rare Disease
4.2.2 Cloud and Hybrid Compute Adoption
4.2.3 AI and Machine Learning Convergence With Genomic Pipelines
4.2.4 Declining Sequencing Cost and Population-Scale Programs
4.2.5 Regulatory Recognition of Genomic Software as a Medical Device
4.2.6 Federated and Privacy-Preserving Multi-Institutional Analysis
4.3 Market Restraints
4.3.1 Fragmented Data-Privacy and Data-Sovereignty Requirements
4.3.2 Shortage of Clinically Trained Bioinformaticians and Validation Experts
4.3.3 Long-Term Genomic Storage and Compute Cost
4.3.4 Legacy LIMS and EHR Interoperability Gaps
4.4 Value Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Offering
5.1.1 Software
5.1.1.1 Primary Data Analysis Software
5.1.1.2 Secondary Analysis Software
5.1.1.3 Tertiary Analysis and Interpretation Software
5.1.1.4 Data Management and Storage Tools
5.1.1.5 Workflow Management Software
5.1.2 Services
5.1.2.1 Data Analysis Services
5.1.2.2 Data Management and Storage Services
5.1.2.3 Pipeline Development and Customization
5.1.2.4 Other Services
5.2 By Workflow
5.2.1 Primary Analysis
5.2.2 Secondary Analysis
5.2.3 Tertiary Analysis
5.3 By Deployment Mode
5.3.1 Cloud-Based
5.3.2 On-Premise
5.3.3 Hybrid
5.4 By Application
5.4.1 Clinical Diagnostics
5.4.2 Drug Discovery and Development
5.4.3 Precision Medicine
5.4.4 Genomic Research
5.4.5 Other Applications
5.5 By End User
5.5.1 Academic and Research Institutes
5.5.2 Hospitals and Clinical Laboratories
5.5.3 Pharmaceutical and Biotechnology Companies
5.5.4 Contract Research Organizations
5.5.5 Other End Users
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East and Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East and Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
6.3.1 Agilent Technologies, Inc.
6.3.2 BGI Genomics Co., Ltd.
6.3.3 Congenica Ltd.
6.3.4 DNAnexus, Inc.
6.3.5 DNASTAR, Inc.
6.3.6 Eurofins Scientific SE
6.3.7 F. Hoffmann-La Roche Ltd
6.3.8 Fabric Genomics, Inc.
6.3.9 Geneious Biomatters Ltd.
6.3.10 Golden Helix, Inc.
6.3.11 Illumina, Inc.
6.3.12 Oxford Nanopore Technologies plc
6.3.13 Pacific Biosciences of California, Inc.
6.3.14 Partek Incorporated
6.3.15 QIAGEN N.V.
6.3.16 Revvity, Inc.
6.3.17 Sentieon Inc.
6.3.18 Seven Bridges Genomics, Inc.
6.3.19 SOPHiA GENETICS SA
6.3.20 Thermo Fisher Scientific Inc.
7 Market Opportunities and Future Outlook
7.1 White-Space and Unmet-Need Assessment

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Congenica Ltd.
  • DNAnexus, Inc.
  • DNASTAR, Inc.
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Fabric Genomics, Inc.
  • Geneious Biomatters Ltd.
  • Golden Helix, Inc.
  • Illumina, Inc.
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • Partek Incorporated
  • QIAGEN N.V.
  • Revvity, Inc.
  • Sentieon Inc.
  • Seven Bridges Genomics, Inc.
  • SOPHiA GENETICS SA
  • Thermo Fisher Scientific Inc.